chs-114
chs-114: sourced relationships with 1 company · 2 clinical trials tracked.
chs-114 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could chs-114 → CHRS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Coherus Oncology, Inc. (CHRS) Metastatic Solid Tumor; Advanced Solid Tumor | Phase 1 |
Clinical Trial Registry Records (2)
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors
Primary endpoint: [Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT)
Frequently asked questions
Which companies have sourced relationships with chs-114?
chs-114 has dated SEC/FDA relationship records for Coherus Oncology, Inc..
How many clinical trials involve chs-114?
BioSniper tracks 2 clinical trials involving chs-114.